Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice

International Journal of Toxicology

Volumn 30, Issue 3, 2011, Pages 322-333

  Sazani, Peter ^a   Ness, Kirk P Van ^a   Weller, Doreen L ^a   Poage, Duane ^b   Nelson, Keith ^b   Shrewsbury, And Stephen B ^a  

^a AVI BioPharma   (United States)

^b MPI RESEARCH   (United States)

Author keywords

alternative splicing; antisense; exon skipping; phosphorodiamidate morpholino oligomers; toxicology

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AVI 4225; DYSTROPHIN; ETEPLIRSEN; MORPHOLINE DERIVATIVE; NITROGEN; OLIGOMER; PHOSPHORAMIDIC ACID DERIVATIVE; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG; UREA;

ANIMAL EXPERIMENT; ARTICLE; BASOPHILIA; CELL VACUOLE; CONTROLLED STUDY; DRUG MECHANISM; EXON SKIPPING; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; WILD TYPE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; EXONS; MICE; MICE, INBRED MDX; MORPHOLINOS; OLIGONUCLEOTIDES; ORGAN SIZE;

ANIMALIA; MUS;

EID: 79960663328     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581811403504     Document Type: Article

References (35)

1. Emery A, Muntoni F Duchenne Muscular Dystrophy. Emery A Muntoni F, ed. 3rd ed. Oxford: Oxford University Press ; 2003: 26-45.
2. Hoffman EP, Brown RH, Jr., Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987 ; 51 (6). 919-928
3. Banks GB, Chamberlain JS. The value of mammalian models for Duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol. 2008 ; 84: 431-453
4. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science. 1989 ; 244 (4912). 1578-1580 (Pubitemid 19189735)
5. Coulton GR, Morgan JE, Partridge TA, Sloper JC. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol. 1988 ; 14 (1). 53-70
6. Pastoret C. Sebille A. mdx mice show progressive weakness and muscle deterioration with age. J Neurol Sci. 1995 ; 129 (2). 97-105
7. Quinlan JG, Hahn HS, Wong BL, Lorenz JN, Wenisch AS, Levin LS. Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord. 2004 ; 14 ((8-9)). 491-496 (Pubitemid 39141704)
8. Stedman HH, Sweeney HL, Shrager JB, et al. The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature. 1991 ; 352 (6335). 536-539
9. Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. Faseb J. 2007 ; 21 (9). 2195-2204 (Pubitemid 47026454)
10. Brazeau GA, Mathew M, Entrikin RK. Serum and organ indices of the mdx dystrophic mouse. Res Commun Chem Pathol Pharmacol. 1992 ; 77 (2). 179-189
11. Emery AE. The muscular dystrophies. Lancet. 2002 ; 359 (9307). 687-695 (Pubitemid 34203773)
12. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet. 1998 ; 7 (7). 1083-1090 (Pubitemid 28306871)
13. Takeshima Y, Wada H, Yagi M, et al. Oligonucleotides against a splicing enhancer sequence led to dystrophin production in muscle cells from a Duchenne muscular dystrophy patient. Brain Dev. 2001 ; 23 (8). 788-790 (Pubitemid 33101867)
14. Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord. 1999 ; 9 (5). 330-338 (Pubitemid 29301716)
15. van Deutekom JC, Bremmer-Bout M, Janson AA, et al. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet. 2001 ; 10 (15). 1547-1554 (Pubitemid 32734306)
16. Hudziak RM, Barofsky E, Barofsky DF, Weller DL, Huang SB, Weller DD. Resistance of morpholino phosphorodiamidate oligomers to enzymatic degradation. Antisense Nucleic Acid Drug Dev. 1996 ; 6 (4). 267-272 (Pubitemid 27045903)
17. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med. 2006 ; 12 (2). 175-177 (Pubitemid 43214742)
18. Ahmad A, Brinson M, Hodges BL, Chamberlain JS, Amalfitano A. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet. 2000 ; 9 (17). 2507-2515
19. Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther. 2007 ; 18 (9). 798-810 (Pubitemid 47502846)
20. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009 ; 8 (10). 918-928
21. Sazani P, Weller DL, Shrewsbury SB. Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol. 2010 ; 29 (2). 143-156
22. Lewis RW, Billington R, Debryune E, Gamer A, Lang B, Carpanini F. Recognition of adverse and nonadverse effects in toxicity studies. Toxicol Pathol. 2002 ; 30 (1). 66-74 (Pubitemid 34194560)
23. Crooke ST. Antisense Drug Technology: Principles, Strategies, and Applications. 2 nd ed Boca Raton: CRC Press ; 2008 :
24. Henry SP, Templin MV, Gillett N, Rojko J, Levin AA. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1. Toxicol Pathol. 1999 ; 27 (1). 95-100 (Pubitemid 29075751)
25. Henry SP, Novotny W, Leeds J, Auletta C, Kornbrust DJ. Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 1997 ; 7 (5). 503-510 (Pubitemid 27491373)
26. Goebl N, Berridge B, Wroblewski VJ, Brown-Augsburger PL. Development of a sensitive and specific in situ hybridization technique for the cellular localization of antisense oligodeoxynucleotide drugs in tissue sections. Toxicol Pathol. 2007 ; 35 (4). 541-548 (Pubitemid 46911888)
27. Monteith DK, Horner MJ, Gillett NA, et al. Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys. Toxicol Pathol. 1999 ; 27 (3). 307-317 (Pubitemid 29245041)
28. In Vivo Methodologies Used to Assess Renal Function. Sipes IG McQueen CA Gandolfi AJ, ed. Oxford, England: Elsevier ; 1997 :
29. Sistare FD, Dieterle F, Troth S, et al. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat Biotechnol. 2010 ; 28 (5). 446-454
30. Grounds MD, Radley HG, Lynch GS, Nagaraju K, De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis. 2008 ; 31 (1). 1-19
31. Van Hoof VO, De Broe ME. Interpretation and clinical significance of alkaline phosphatase isoenzyme patterns. Crit Rev Clin Lab Sci. 1994 ; 31 (3). 197-293 (Pubitemid 24320319)
32. Schmidt A. The significance of the detection of alkaline phosphatase in the diagnosis of neuromuscular diseases. Biomed Biochim Acta. 1986 ; 45 ((1-2)). S115 - S117
33. Cooper BJ. Animal models of Duchenne and Becker muscular dystrophy. Br Med Bull. 1989 ; 45 (3). 703-718 (Pubitemid 19189376)
34. Kohli R, Harris DC, Whitington PF. Relative elevations of serum alanine and aspartate aminotransferase in muscular dystrophy. J Pediatr Gastroenterol Nutr. 2005 ; 41 (1). 121-124 (Pubitemid 40967367)
35. Connolly AM, Pestronk A, Planer GJ, Yue J, Mehta S, Choksi R. Congenital muscular dystrophy syndromes distinguished by alkaline and acid phosphatase, merosin, and dystrophin staining. Neurology. 1996 ; 46 (3). 810-814 (Pubitemid 26100066)